SeaStar Medical Holding (ICU)
NASDAQ:ICU
Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$2.30
-$0.08(-3.90%)
At close: 4:00 PM EST
$2.30
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$2.07 - $12.50
Previous CloseN/A
Volume52.61K
Average Volume (3M)3.06M
Market Cap
$10.91M
Enterprise Value$1.51M
Total Cash (Recent Filing)$9.35M
Total Debt (Recent Filing)$331.00K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 18, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding3,997,002
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$8.00Price Target Upside247.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 90% reflect a device-plus-consumable business model that can scale profitably as utilization grows. High unit economics mean incremental revenue can quickly flow to the bottom line once fixed costs and commercialization scale are achieved, supporting durable operating leverage.
Pivotal Trial ProgressMaterial enrollment progress in the pivotal NEUTRALIZE‑AKI trial reduces regulatory execution risk and meaningfully increases the probability of a clinical readout and subsequent approval pathway. Successful trial completion would unlock adult market access and broader durable commercial adoption.
Low Leverage / Stronger EquityA very low debt load and recovering equity base improve financial flexibility versus typical clinical-stage peers, lowering bankruptcy and interest‑coverage risk. This capital structure provides runway advantages for clinical and commercialization milestones over the next several quarters.
Bears Say
Heavy Cash BurnConsistent negative operating and free cash flow at roughly -$13.7M TTM creates ongoing financing necessity. This elevates dilution and execution risk, as management must secure capital to fund R&D, trial completion and commercialization before revenues can sustainably cover cash needs.
Small Commercial BaseRevenue remains nascent and concentrated (ultra-rare pediatric use case), limiting predictable recurring cash flows. Small absolute sales volumes make scaling fixed commercialization costs difficult and leave operating results highly sensitive to a few centers or case volumes over the medium term.
Significant Share DilutionMarked dilution in the past year materially reduces per‑share economic ownership and indicates prior funding stress. Continued need to raise capital to support trials and commercialization could further dilute returns and constrain long‑term shareholder value accumulation.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $12.50 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $10.91M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Aug 18, 2026 which is in 66 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on May 13, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.075.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.97.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,997,002 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
ICU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial and clinical momentum: notable YoY revenue growth (+69%), seven new hospital customers in Q1, completion of the SAVE Registry enrollment (50 patients), substantial trial progress (198/339 enrolled, ~58%) and a stronger cash position (+~79% YoY). Management emphasized high gross margins (>90%), disciplined operating spend and active FDA engagement on potential accelerated pathways. Offsetting this progress are the small absolute revenue base ($495k Q1), continued quarterly net losses (~$3.5M), dependence on ultra-rare pediatric case flow for adoption, ongoing enrollment and regulatory risks, and notable share dilution. Overall, the call presents meaningful early-stage commercial validation and clinical progress but also highlights typical execution and regulatory risks for a clinical-stage medical device company.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$8.00
▲(247.83% Upside)
Technical Analysis
Ownership Overview
2.96% Insiders
1.32% Mutual Funds
<0.01% Other Institutional Investors
94.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---